Company intelligence / Profile preview

Anrun Pharmaceutical Technology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Anrun Pharmaceutical Technology has multiple small molecule drugs in preclinical to phase 2 development, with a lead program (AMX-3009 Maleate) in phase 2 for non-small cell lung cancer and others in preclinical for cancer indications. The company does not currently have marketed products or published late-stage results.[4][7]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

AMX3009

Unknown

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Anrun Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anrun Pharmaceutical Technology.

Explore the full profile